These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 17222687)

  • 21. Editorial comment on: Intraprostatic and bladder-neck injection of botulinum A toxin in treatment of males with bladder-neck dyssynergia: a pilot study.
    Pickard R
    Eur Urol; 2008 Mar; 53(3):626. PubMed ID: 17950524
    [No Abstract]   [Full Text] [Related]  

  • 22. Botulinum toxin A for overactive bladder and detrusor muscle overactivity in patients with Parkinson's disease and multiple system atrophy.
    Giannantoni A; Rossi A; Mearini E; Del Zingaro M; Porena M; Berardelli A
    J Urol; 2009 Oct; 182(4):1453-7. PubMed ID: 19683298
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Editorial comment on: neurogenic detrusor overactivity treated with english botulinum toxin a: 8-year experience of one single centre.
    Wyndaele JJ
    Eur Urol; 2008 May; 53(5):1019-20. PubMed ID: 17950988
    [No Abstract]   [Full Text] [Related]  

  • 24. Editorial comment on: Urinary nerve growth factor levels are elevated in patients with detrusor overactivity and decreased in responders to detrusor botulinum toxin-A injection.
    Novara G
    Eur Urol; 2009 Oct; 56(4):706-7. PubMed ID: 18472211
    [No Abstract]   [Full Text] [Related]  

  • 25. Has botulinum toxin therapy come of age: what do we know, what do we need to know, and should we use it?
    da Silva CM; Cruz F
    Curr Opin Urol; 2009 Jul; 19(4):347-52. PubMed ID: 19444121
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Editorial comment.
    Blok BF
    Urology; 2010 Mar; 75(3):558. PubMed ID: 20211368
    [No Abstract]   [Full Text] [Related]  

  • 27. The second-line management of idiopathic overactive bladder: what is the place of sacral neuromodulation and botulinum toxin-A in contemporary practice?
    Chapple C; De Ridder D
    BJU Int; 2009 Nov; 104(9):1188-90. PubMed ID: 19681899
    [No Abstract]   [Full Text] [Related]  

  • 28. Suburothelial myofibroblasts in the human overactive bladder and the effect of botulinum neurotoxin type A treatment.
    Roosen A; Datta SN; Chowdhury RA; Patel PM; Kalsi V; Elneil S; Dasgupta P; Kessler TM; Khan S; Panicker J; Fry CH; Brandner S; Fowler CJ; Apostolidis A
    Eur Urol; 2009 Jun; 55(6):1440-8. PubMed ID: 19054608
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efficacy and complications of intradetrusor injection with botulinum toxin A in patients with refractory idiopathic detrusor overactivity.
    Jeffery S; Fynes M; Lee F; Wang K; Williams L; Morley R
    BJU Int; 2007 Dec; 100(6):1302-6. PubMed ID: 17979928
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efficacy of botulinum toxin-A for treating idiopathic detrusor overactivity: results from a single center, randomized, double-blind, placebo controlled trial.
    Sahai A; Khan MS; Dasgupta P
    J Urol; 2007 Jun; 177(6):2231-6. PubMed ID: 17509328
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Will suburothelial injection of small dose of botulinum A toxin have similar therapeutic effects and less adverse events for refractory detrusor overactivity?
    Kuo HC
    Urology; 2006 Nov; 68(5):993-7; discussion 997-8. PubMed ID: 17113890
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy and tolerability of botulinum toxin type A in patients with neurogenic detrusor overactivity and without concomitant anticholinergic therapy: comparison of two doses.
    Grise P; Ruffion A; Denys P; Egon G; Chartier Kastler E
    Eur Urol; 2010 Nov; 58(5):759-66. PubMed ID: 20674149
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Best treatment for overactive bladder if behavioral treatment and anticholinergics fail. Onabotulinumtoxina.
    Doggweiler R
    J Urol; 2011 Jun; 185(6):2023-4. PubMed ID: 21496846
    [No Abstract]   [Full Text] [Related]  

  • 34. Trigonal injection of botulinum toxin-A does not cause vesicoureteral reflux in neurogenic patients.
    Mascarenhas F; Cocuzza M; Gomes CM; Leão N
    Neurourol Urodyn; 2008; 27(4):311-4. PubMed ID: 17914742
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Efficacy of repeat injections of botulinum A toxin to the detrusor in neurogenic bladder overactivity].
    Chenet A; Perrouin-Verbe B; Le Normand L; Labat JJ; Brunel P; Lefort M; Mathé JF
    Ann Readapt Med Phys; 2007 Nov; 50(8):651-60. PubMed ID: 17490775
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Safety and tolerability of sedation-free flexible cystoscopy for intradetrusor botulinum toxin-A injection.
    Cohen BL; Rivera R; Barboglio P; Gousse A
    J Urol; 2007 Mar; 177(3):1006-10; discussion 1010. PubMed ID: 17296397
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prospects and limitations of treatment with botulinum neurotoxin type A for patients with refractory idiopathic detrusor overactivity.
    Schmid DM; Roy S; Sulser T; Scheiner D
    BJU Int; 2008 Jul; 102 Suppl 1():7-10. PubMed ID: 18665972
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Histological changes in the urothelium and suburothelium of human overactive bladder following intradetrusor injections of botulinum neurotoxin type A for the treatment of neurogenic or idiopathic detrusor overactivity.
    Apostolidis A; Jacques TS; Freeman A; Kalsi V; Popat R; Gonzales G; Datta SN; Ghazi-Noori S; Elneil S; Dasgupta P; Fowler CJ
    Eur Urol; 2008 Jun; 53(6):1245-53. PubMed ID: 18343564
    [TBL] [Abstract][Full Text] [Related]  

  • 39. What a patient with refractory idiopathic detrusor overactivity should know about botulinum neurotoxin type a injection.
    Khan S; Kessler TM; Apostolidis A; Kalsi V; Panicker J; Roosen A; Gonzales G; Haslam C; Elneil S; Fowler CJ; Dasgupta P
    J Urol; 2009 Apr; 181(4):1773-8. PubMed ID: 19233414
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Short-term efficacy of botulinum toxin a for refractory overactive bladder in the elderly population.
    White WM; Pickens RB; Doggweiler R; Klein FA
    J Urol; 2008 Dec; 180(6):2522-6. PubMed ID: 18930481
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.